First Week of February 2026 Options Trading For Arrowhead Pharmaceuticals (ARWR)

Arrowhead Pharmaceuticals (ARWR) is presented with actionable options ideas: a $67.50 put trading at a $4.20 bid (stock price $69.17) would obligate purchase at $67.50 but nets a cost basis of $63.30 and carries a 61% chance to expire worthless, equating to a 6.22% return (38.49% annualized) if it does. On the call side, a $70.00 call bid is $7.20; selling covered calls at that strike against $69.17 shares would yield 11.61% if called at Feb 2026 expiry, with a 44% probability of expiring worthless and a 10.41% yield boost (64.40% annualized). Implied volatilities are ~72–73% (vs. 71% trailing-12m), and the piece frames these metrics as income-oriented trade ideas while noting upside caps and the need to review company fundamentals.

Analysis

Market structure: The immediate winners are option sellers and income-focused strategies — selling the ARWR Feb‑2026 $67.50 put for $4.20 yields a 6.22% cash return (38.5% annualized) and selling the $70 call for $7.20 boosts carry to 11.6% (64.4% annualized). With IV ≈72% ≈ realized vol (71%), option premia look fair, not richly overpriced, so flows will favor repeat income sellers rather than directional speculators. This increases short‑gamma exposure in small‑cap biotech, concentrating liquidity risk around binary events.

Risk assessment: Tail risks are classic biotech binaries — a single negative trial or FDA setback could gap ARWR >50% (low‑probability, high‑impact). Immediate (days) risk is IV and spreads; short term (weeks/months) is event concentration and IV spikes; long term depends on R&D readouts, partnerships and cash runway. Hidden deps include borrow/margin costs if assigned, sector‑wide vol correlation, and tax/assignment timing; catalysts to watch: announced clinical readouts, partner decisions, and quarterly cash burn projections over the next 30–180 days.

Trade implications: For size-controlled exposure, prefer cash‑secured puts: sell ARWR Feb‑2026 $67.50 for $4.20 to acquire at $63.30 (size 1–3% portfolio), with rule to close if IV falls >15% or underlying >$76 (10%+). If already long, implement covered calls by selling Feb‑2026 $70 for $7.20 to lock 11.6% to expiry; consider collars (buy $60 puts) if downside protection to −20% is required. Use a relative hedge: long ARWR / short 0.5x XBI to neutralize sector beta during event windows.

Contrarian angles: The market underestimates assignment risk — a 39% chance of assignment implies meaningful capital concentration if multiple sellers get exercised; reported annualized YieldBoosts (38–64%) understate binary downside. Historical parallels (biotech trial shocks) show >60% drawdowns; thus income capture should be capped and hedged. Unintended consequences: mass assignment can force sellers to liquidate other positions, amplifying downside—plan liquidity and stop thresholds accordingly.

Key Decisions for Investors

• Sell a cash‑secured put: sell ARWR Feb‑2026 $67.50 for $4.20 to target an effective entry at $63.30; size 1–2% of portfolio (max 3%). Close the short if IV drops >15% from current or underlying >$76 (≈+10%) or if position would represent >5% concentrated exposure after assignment.
• If already long ARWR, sell the Feb‑2026 $70 call for $7.20 (covered call) to realize an 11.6% return to expiry; cap net position to 2–3% portfolio and buy a $60 put (or equivalent) if you require downside protection to limit losses beyond −20%.
• Use a collar instead of naked put selling if unwilling to accept binary risk: buy 100 shares only if net cost ≤ $63.30 (after selling $67.50 put and $70 call) and buy a $60 protective put for defined downside, funding via selling the $70 call.
• Pair trade to neutralize sector risk: go long ARWR (size 2%) and short 0.5x notional of XBI to reduce beta ahead of expected clinical/earnings windows over next 30–180 days; rebalance post‑readout.
• Set alerts and exit triggers: monitor ARWR press releases for trial/FDA dates and cash burn guidance over the next 30–180 days; liquidate or hedge if a negative readout is announced or if ARWR gaps down >20% intraday (sell into liquidity within 1 trading day).